摘要
目的:探讨50岁以上急性髓系白血病患者生存情况和预后影响因素。方法:回顾性分析本院2016年1月至2021年6月收治的50岁以上急性髓系白血病患者共222例的临床资料,采用Kaplan-Meier方法评估总体生存率,Cox回归模型评估预后影响因素。结果:全部患者1、3年总体生存率分别为46.8%、28.8%,随访时间段内获得缓解的患者复发率为57%。单因素及多因素分析结果均显示,年龄大、MLL家族融合基因、PHF6基因突变、TP53基因突变、不耐受标准的治疗方案、未获得完全缓解、复杂染色体核型、+mar染色体核型、inv(3)染色体核型与不良预后显著相关(均P<0.05)。融合基因阴性、AML-ETO融合基因阳性在本研究人群中无明显生存优势。在获得完全缓解的患者中,是否获得MRD阴性的患者总体生存率无显著差异。结论:50岁以上急性髓系白血病患者总体预后差,复发率高,预后受多因素影响且有该人群自身特点。
Objective:To explore the overall survival and prognostic factors of patients over 50 years old with acute myeloid leukemia(AML).Methods:The clinical data of 222 AML patients aged over 50 years in our hospital from January 2016 and June 2021 were retrospectively analyzed.Kaplan-Meier method was used to evaluate the overall survival(OS)rate,and Cox regression model to evaluate the prognostic factors.Results:The 1-year and 3-year OS rates of all patients were 46.8%and 28.8%,respectively.The recurrence rate of patients who achieved remission during follow-up time was 57%.Both univariate and multivariate analysis showed that advanced age,MLL family fusion gene,PHF6 gene mutation,TP53 gene mutation,intolerance to standard chemotherapy,incomplete remission,complex karyotype,+mar karyotype and inv(3)karyotype were significantly correlated with prognosis(all P<0.05).Negative fusion gene and positive AML-ETO fusion gene had no obvious survival advantage in this population.In patients with complete remission,there was no significant survival advantage in those who achieved minimal residual disease negative.Conclusion:AML patients aged over 50 years have a poor outcome and high recurrence rate.The prognosis is affected by multiple factors and has its own characteristics.
作者
刘红
李智
史玉叶
陶善东
王春玲
于亮
LIU Hong;LI Zhi;SHI Yu-Ye;TAO Shan-Dong;WANG Chun-Ling;YU Liang(Department of Hematology,The Affiliated Husian No.1 People's Hospital of Nanjing Medical Universily,Key Laboratory of Henutology,Nanjing Medical University;Department of Breast and Thyroid Surgey,The Affiliated Huaian No.1 People's Hospital of Narnjing Medical Universiry,Huaian 223300,Jiangsu Province,China)
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2024年第4期1039-1045,共7页
Journal of Experimental Hematology
